These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For research use only.  Legal & Disclaimer

Practitioner Intelligence

Regulatory clarity for
research professionals

We track FDA actions, policy shifts, and compound-level developments so you don't have to. Updated monthly — plain English, no noise.

Subscribe to Regulatory Pulse View Latest Update →

Monthly Briefing

Regulatory Pulse — Monthly Briefing

Every month, Sequence Labs publishes a plain-English summary of FDA actions, 503A bulks list changes, FTC enforcement trends, and policy developments that affect licensed practitioners working with research compounds. No marketing. No promotions. Compliance intelligence only.

Sent once per month. No spam. Unsubscribe anytime. team@sequencelabs.health

Coverage Areas

What We Track

FDA 503A Bulks List

We monitor every addition, removal, and advisory committee decision that affects compoundable peptides. When the list changes, we update our catalog and notify subscribers.

FTC Enforcement Actions

We track FTC actions against supplement and peptide suppliers for advertising claims violations. Signals when the regulatory climate is tightening.

Warning Letters & Import Alerts

FDA warning letters naming specific compounds or supplier practices are early indicators of enforcement direction. We flag anything affecting research peptide suppliers.

Practitioner Marketing Rules

CAN-SPAM compliance, B2B email marketing rules, and practitioner-facing advertising guidance — we track changes that affect how licensed professionals communicate about research compounds.

Current Regulatory Landscape

What We're Watching Right Now

Compiled June 2026. For research informational purposes. Not legal advice. Sequence Labs is not a law firm.

Active — Monitor June 2026

PCAC July 23–24, 2026 — Seven Peptides Under Advisory Review

The FDA's Pharmacy Compounding Advisory Committee convenes July 23–24 at FDA White Oak Campus to review seven compounds for the 503A bulks list: BPC-157 (ulcerative colitis), KPV (wound healing), TB-500 (wound healing), MOTS-c (obesity/osteoporosis), DSIP/Emideltide (opioid withdrawal), Semax (cerebral ischemia), and Epitalon (insomnia). Favorable rulings add these compounds to the approved list for licensed compounding pharmacies. Sequence Labs has submitted a public comment in support. Tracking number: mq2-q77h-msht.

Watch June 2026

Thymosin Alpha-1 Advisory Committee Review — Also July 23

Thymosin Alpha-1 has a separate FDA advisory committee review scheduled for July 23, 2026. TA-1 is a known gap in many research peptide catalogs. Outcome of this review will determine compounding pharmacy eligibility and affect supplier demand significantly.

Resolved March 2026

RFK Jr. / HHS Restored 14 Peptides — March 2026

In March 2026, HHS under Secretary Kennedy restored 14 previously restricted peptides to the 503A bulks list, reversing earlier FDA restrictions. This restoration significantly broadened the legal compounding landscape for licensed practitioners. The current PCAC review is the next scheduled action in that ongoing policy evolution.

Enforcement Precedent March 2026

Gram Peptides FDA Warning Letter — March 31, 2026

The FDA issued a warning letter to Gram Peptides on March 31, 2026 citing prohibited claims including: injection/administration language, body effect claims, and human use framing on a research-only product. This letter defines the current enforcement standard for research peptide suppliers. Sequence Labs copy standards are built around compliance with this ruling.

View FDA Warning Letter — Gram Peptides (March 31, 2026) →

Regulatory Calendar

Key Dates

Jun 30
2026

Deadline to register for oral comment at PCAC July hearing

Jul 9
2026

FDA public comment deadline — Docket FDA-2025-N-6895✓

Sequence Labs comment submitted

Jul 22
2026

PCAC docket closes

Jul 23–24
2026

PCAC Meeting — FDA White Oak Campus

Seven peptides under review: BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, Epitalon. Plus Thymosin Alpha-1 separately.

Feb
2027

Next PCAC Meeting

Compounds under review: GHK-Cu, CJC-1295, Ipamorelin, Melanotan II, Thymosin Alpha-1, LL-37, Dihexa

About This Resource

Why Sequence Labs Tracks This

Sequence Labs is not a law firm and this is not legal advice. We publish this intelligence because we believe practitioners working with research compounds deserve accurate, timely information about the regulatory environment — not marketing copy. Our Catalog Integrity Protocol, reviewed by Sabrina Runbeck PA-C, is updated in response to regulatory developments covered here.

View the Catalog Integrity Protocol →
For research use only. Not for human use. All information on this page is for informational purposes and does not constitute legal or medical advice.